DSpace Repository

Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience

Show simple item record

dc.contributor.author Beköz, H.
dc.contributor.author Karadurmuş, N.
dc.contributor.author Paydaş, S.
dc.contributor.author Türker, A.
dc.contributor.author Toptaş, T.
dc.contributor.author Firatli Tuğlular, T.
dc.contributor.author Sönmez, M.
dc.contributor.author Gülbaş, Z.
dc.contributor.author Tekgündüz, E.
dc.contributor.author Kaya, A.H.
dc.contributor.author Özbalak, M.
dc.contributor.author Taştemir, N.
dc.contributor.author Kaynar, L.
dc.contributor.author Yildirim, R.
dc.contributor.author Karadoğan, I.
dc.contributor.author Arat, M.
dc.contributor.author Pepedil Tanrikulu, F.
dc.contributor.author özkocaman, V.
dc.contributor.author Abali, H.
dc.contributor.author Turgut, M.
dc.contributor.author Kurt Yüksel, M.
dc.contributor.author Özcan, M.
dc.contributor.author Doğu, M.H.
dc.contributor.author Kabukçu Hacioğlu, S.
dc.contributor.author Barişta, I.
dc.contributor.author Demirkaya, M.
dc.contributor.author Köseoğlu, F.D.
dc.contributor.author Toprak, S.K.
dc.contributor.author Yilmaz, M.
dc.contributor.author Demirkürek, H.C.
dc.contributor.author Demirkol, O.
dc.contributor.author Ferhanoğlu, B.
dc.date.accessioned 2019-08-16T12:59:48Z
dc.date.available 2019-08-16T12:59:48Z
dc.date.issued 2017
dc.identifier.issn 09237534 (ISSN)
dc.identifier.uri http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/9317
dc.description.abstract Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile. Patients and methods: We present a retrospective analysis of 82 patients (median age: 30 years; range: 18-75) with relapsed/refractory HL treated with nivolumab in a named patient program from 24 centers throughout Turkey. The median follow-up was 7 months, and the patients had a median of 5 (2-11) previous lines of therapy. Fifty-seven (70%) and 63 (77%) had been treated by stem-cell transplantation and brentuximab vedotin, respectively. Results: Among 75 patients evaluated after 12 weeks of nivolumab treatment, the objective response rate was 64%, with 16 complete responses (CR; 22%); after 16 weeks, it was 60%, with 16 (26%) patients achieving CR. Twenty patients underwent subsequent transplantation. Among 11 patients receiving allogeneic stem-cell transplantation, 5 had CR at the time of transplantation and are currently alive with ongoing response. At the time of analysis, 41 patients remained on nivolumab treatment. Among the patients who discontinued nivolumab, the main reason was disease progression (n = 19). The safety profile was acceptable, with only four patients requiring cessation of nivolumab due to serious adverse events (autoimmune encephalitis, pulmonary adverse event, and two cases of graft-versus-host disease aggravation). The 6-month overall and progression-free survival rates were 91.2% (95% confidence interval: 0.83-0.96) and 77.3% (0.66-0.85), respectively. Ten patients died during the follow-up; one of these was judged to be treatment-related. Conclusions: Nivolumab represents a novel option for patients with cHL refractory to brentuximab vedotin, and may serve as a bridge to transplantation; however, it may be associated with increased toxicity. © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
dc.language.iso English
dc.publisher Oxford University Press
dc.relation.isversionof 10.1093/annonc/mdx341
dc.subject Hodgkin lymphoma
dc.subject Nivolumab
dc.subject Programmed death 1 (PD-1) blocker
dc.subject Resistant/relapsed disease
dc.subject brentuximab vedotin
dc.subject mycophenolate mofetil
dc.subject nivolumab
dc.subject programmed death 1 receptor
dc.subject steroid
dc.subject antibody conjugate
dc.subject antineoplastic agent
dc.subject monoclonal antibody
dc.subject abdominal pain
dc.subject adult
dc.subject aged
dc.subject allergic encephalitis
dc.subject allogeneic stem cell transplantation
dc.subject anemia
dc.subject arthritis
dc.subject Article
dc.subject cancer growth
dc.subject cancer mortality
dc.subject cancer pain
dc.subject cancer recurrence
dc.subject cancer survival
dc.subject chronic graft versus host disease
dc.subject controlled study
dc.subject decreased appetite
dc.subject diarrhea
dc.subject drug efficacy
dc.subject drug response
dc.subject drug safety
dc.subject edema
dc.subject encephalitis
dc.subject fatigue
dc.subject female
dc.subject fever
dc.subject graft versus host reaction
dc.subject gynecomastia
dc.subject headache
dc.subject Hodgkin disease
dc.subject human
dc.subject hypercalcemia
dc.subject hypertransaminasemia
dc.subject hypocalcemia
dc.subject hypophosphatemia
dc.subject hypothyroidism
dc.subject infection
dc.subject infusion related reaction
dc.subject lung disease
dc.subject lymphocytopenia
dc.subject major clinical study
dc.subject male
dc.subject multicenter study
dc.subject muscle cramp
dc.subject neutropenia
dc.subject overall survival
dc.subject pain
dc.subject pancreatitis
dc.subject peripheral neuropathy
dc.subject photopheresis
dc.subject pneumonia
dc.subject priority journal
dc.subject progression free survival
dc.subject pruritus
dc.subject rash
dc.subject retrospective study
dc.subject scrotal pain
dc.subject septic shock
dc.subject stem cell transplantation
dc.subject stomatitis
dc.subject thrombocytopenia
dc.subject Turkey (republic)
dc.subject upper respiratory tract infection
dc.subject visual disorder
dc.subject adolescent
dc.subject clinical trial
dc.subject disease free survival
dc.subject middle aged
dc.subject young adult
dc.subject Adolescent
dc.subject Adult
dc.subject Aged
dc.subject Antibodies, Monoclonal
dc.subject Antineoplastic Agents
dc.subject Disease-Free Survival
dc.subject Female
dc.subject Hodgkin Disease
dc.subject Humans
dc.subject Immunoconjugates
dc.subject Male
dc.subject Middle Aged
dc.subject Retrospective Studies
dc.subject Stem Cell Transplantation
dc.subject Young Adult
dc.title Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
dc.type Article
dc.relation.journal Annals of Oncology
dc.identifier.volume 28
dc.identifier.issue 10
dc.identifier.startpage 2496
dc.identifier.endpage 2502
dc.identifier.index Scopus


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record